Skip to main content
. Author manuscript; available in PMC: 2013 Sep 30.
Published in final edited form as: Ann Rheum Dis. 2007 Oct 30;67(8):1076–1083. doi: 10.1136/ard.2007.078048

Figure 5.

Figure 5

Conjoint effects of CCR5 and CCL3L1 on systemic lupus erythaematosus (SLE) susceptibility, development of renal lupus and autoantibody titres. A. CCL3L1–CCR5 genotypic groups. Group 1 comprised of subjects who did not possess CCR5 human haplogroup (HH)E or HHG*2 (Non-HHE and Non-HHG*2) and had two copies of CCL3L1. Group 2 comprised of subjects who either (a) did not possess CCR5 HHE or HHG*2 (Non-HHE and Non- HHG*2) and had either <2 or >2 copies of CCL3L1, or (b) those who possessed HHE or HHG*2 and had two copies of CCL3L1. Group 3 comprised of subjects who possessed HHE or HHG*2 CCR5 haplotypes and had <2 or >2 copies of CCL3L1. The color codes for the indicated genotypic risk groups are used in the rest of the figure. B. Association of the genotypic risk groups with risk of SLE. For these analyses, group 1 in (A) was considered as the reference category. For each cohort the odds ratios were estimated in a single model by multivariate logistic regression analysis. Letters (a–h) indicate significance values: a, 0.015; b, 0.041; c, 0.187; d, 0.020; e, 0.283; f, 0.009; g, 0.002; h, <0.001. C. Association of CCL3L1–CCR5 genotypic risk groups with risk of lupus nephritis in patients with SLE from the Colombia and Ohio cohorts. Letters (i) and (j) indicate significance values: i, <0.001; j, 0.071. In (B) and (C) the diamonds and error bars represent point and 95% confidence intervals of odds ratio, respectively. D. Association of the CCL3L1–CCR5 genotypic risk groups and autoantibody titres. Letters (k–n) indicate significance values: k, 0.037; l, 0.006; m, <0.001; n, <0.001. The anti-Ro and anti-La data was not available for the San Antonio cohort. Statistical significance for results shown in (C) and (D) was assessed using clustered multinomial logistic regression analyses.